Remaining Hyland Baby Teething Tablets Recalled

News
Article

Standard Homeopathic Company is recalling all lots of Hyland’s Baby Teething Tablets and Hyland’s Nighttime Baby Teething Tablets due to inconsistent amounts of belladonna alkaloids.

On April 13, 2017, Standard Homeopathic Company announced it is recalling all lots of Hyland’s Baby Teething Tablets and Hyland’s Baby Nighttime Teething Tablets sold in retail stores. The nationwide recall comes after FDA found inconsistent levels of belladonna alkaloids compared with the products’ labels. These inconsistent levels of belladonna could be harmful to children, according to FDA, who says the effects are “unpredictable”.

The teething tablets are used to provide temporary relief of teething symptoms in children.

While the company stopped making and shipping the tablets in October 2016, some product remains on store shelves and in stock rooms. The recall is intended to remove access to the remaining stock.

"We initiated this recall even after discontinuing production last fall because it is appropriate to do what our regulating agency has formally requested,” said J.P. Borneman, PhD, chairman and CEO of Standard Homeopathic Company, in a press release. “We are committed to maintaining and earning the trust consumers have placed in Standard Homeopathic Company. We have worked for 114 years to build relationships with our consumers. We intend to preserve that tradition of trust.”

Source: FDA

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.